# Cytura Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cytura-therapeutics

- Industry: Biotechnology
- Headquarters: Netherlands
- Website: www.cyturatherapeutics.com
- Latest round: Seed (Apr 23, 2019)
- Investors on record: 3

## About

Cytura Therapeutics BV is a Netherlands-based biotechnology company focused on developing therapies that target genomic instability, which is crucial in cancer progression and treatment resistance.Founded in 2018 by Ad Van Gorp, Cytura Therapeutics BV operates in the Netherlands, specifically focusing on innovative cancer therapies. The company has engaged in one funding deal, raising an undisclosed amount in Seed funding on April 23, 2019, led by Thuja Capital with participation from BOM Brabant Ventures and K.U. Leuven Research & Development.Cytura Therapeutics specializes in the development of innovative therapies aimed at addressing genomic instability, a critical issue in cancer progression and treatment resistance. Their core offerings focus on targeting this instability through both standalone and combination therapies, designed to prevent therapy resistance and reduce the likelihood of cancer relapse. These products intend to improve the effectiveness of cancer treatments while enhancing the quality of life for patients globally. The company primarily serves healthcare providers, clinical research institutions, and pharmaceutical partners engaged in cancer treatment, with a focus on North America and Europe.Cytura Therapeutics generates revenue through partnerships with healthcare organizations and pharmaceutical firms, integrating their therapies into existing cancer treatment protocols. The company’s revenue model involves B2B transactions, collaborating with hospitals and research institutions to facilitate the adoption of their genomic instability-targeted therapies. Specific pricing details for their products are not disclosed, but the financial structure may include licensing agreements, research collaborations, and potential subscription models for ongoing support and updates on treatment efficacy.Cytura Therapeutics plans to enhance its product offerings by designing new therapies targeting genomic instability, with specific timelines for these launches yet to be disclosed. The company aims to expand into new markets, particularly in North America and Europe, to increase its global reach. The funding raised in April 2019 will support these initiatives, facilitating research and development efforts to bring new therapies to market and strengthen partnerships with healthcare organizations.

## Funding rounds

- Seed, Apr 23, 2019 — K.U. Leuven Research & Development, Thuja Capital, BOM Brabant Ventures

## Investors

- K.U. Leuven Research & Development (https://capitalatlas.ai/funds/k-u-leuven-research-development) — Seed
- Thuja Capital (https://capitalatlas.ai/funds/thuja-capital) — Seed
- BOM Brabant Ventures (https://capitalatlas.ai/funds/bom-brabant-ventures) — Seed